Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study (vol 4, pg 211, 2016)

被引：1
|
作者：
Weber, M. A.
Mansfield, T. A.
Cain, V. A.
Iqbal, N.
Parikh, S.
Ptaszynska, A.
机构：
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2016年 / 4卷 / 03期
关键词：
D O I：
10.1016/S2213-8587(15)00467-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E3 / E3
页数：1
相关论文
共 50 条
  • [1] Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
    Weber, Michael A.
    Mansfield, Traci A.
    Cain, Valerie A.
    Iqbal, Nayyar
    Parikh, Shamik
    Ptaszynska, Agata
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (03): : 211 - 220
  • [2] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
    Bailey, Clifford J.
    Gross, Jorge L.
    Pieters, Anne
    Bastien, Arnaud
    List, James F.
    LANCET, 2010, 375 (9733): : 2223 - 2233
  • [3] Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study
    Brown, Alexander J. M.
    Lang, Chim
    McCrimmon, Rory
    Struthers, Allan
    BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [4] Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study
    Alexander J.M. Brown
    Chim Lang
    Rory McCrimmon
    Allan Struthers
    BMC Cardiovascular Disorders, 17
  • [5] High dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled study
    Sihag, B.
    Meena, B.
    Agrawal, R.
    Meel, J.
    Sirohi, P.
    Bishnoi, P.
    DIABETES OBESITY & METABOLISM, 2010, 12 : 87 - 88
  • [6] TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
    Burant, Charles F.
    Viswanathan, Prabhakar
    Marcinak, John
    Cao, Charlie
    Vakilynejad, Majid
    Xie, Benhuai
    Leifke, Eckhard
    LANCET, 2012, 379 (9824): : 1403 - 1411
  • [7] HTD1801 improves glycaemic control in patients with type 2 diabetes: double-blind, placebo-controlled, phase 2 study
    Ji, L.
    Ma, J.
    Ma, J.
    Cheng, Z.
    Gan, S.
    Yuan, G.
    Liu, D.
    Li, S.
    Liu, Y.
    Xue, X.
    Bai, J.
    Wang, K.
    Cai, H.
    Li, S.
    Liu, L.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S318 - S319
  • [8] Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes inadequately controlled with metformin and dapagliflozin: a randomised, double-blind, and placebo-controlled study
    Cho, Y.
    Kim, K. -S.
    Lee, B. -W.
    Hong, J.
    Yu, J.
    Lim, S.
    Kim, Y.
    Lee, C.
    Kim, S.
    Kwak, S.
    Lee, W.
    DIABETOLOGIA, 2024, 67 : S322 - S323
  • [9] Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
    Haak, T.
    Meinicke, T.
    Jones, R.
    Weber, S.
    von Eynatten, M.
    Woerle, H. -J.
    DIABETES OBESITY & METABOLISM, 2012, 14 (06): : 565 - 574
  • [10] Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study
    Cai, Xiaoling
    Ji, Linong
    Yuan, Mingxia
    Ma, Jianhua
    Bian, Fang
    Li, Sheli
    Pang, Wuyan
    Yan, Shuang
    Zhou, Huimin
    Hou, Minghui
    Li, Wenhui
    Jia, Ying
    Liu, Li
    Ding, Ke
    Xu, Michael
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 51
12345